Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics, Safety and Tolerability of BI 201335 in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Monocentric, Open-label, Parallel-group, Phase I Trial

Next Previous
Trial Profile

Pharmacokinetics, Safety and Tolerability of BI 201335 in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Monocentric, Open-label, Parallel-group, Phase I Trial

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Faldaprevir (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

  • 01 Oct 2013 Results will be presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) according to a Boehringer Ingelheim media release.
  • 27 Jun 2012 Actual patient number (28) added as reported by ClinicalTrials.gov.
  • 27 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top